BANK VONTOBEL/CALL/BIOGEN IDEC/310/0.01/20.09.24 | Market Closed - Deutsche Boerse AG 19:04:45 17/05/2024 BST | ||
| 0.009 EUR | +12.50% |
|
| 1 month | +350.00% | ||
| 3 months | -59.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.009 | +12.50% |
| 16/05/24 | 0.008 | -46.67% |
| 15/05/24 | 0.015 | +66.67% |
| 14/05/24 | 0.009 | -18.18% |
| 13/05/24 | 0.011 | +22.22% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 07:04 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM3MVT |
| ISIN | DE000VM3MVT3 |
| Date issued | 06/10/2023 |
| Strike | 310 $ |
| Maturity | 20/09/2024 (126 Days) |
| Parity | 100 : 1 |
| Emission price | 0.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.26 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.01 € |
| Spread % | 50.00% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
- Stock Market
- Warrants
- Warrant
